686 related articles for article (PubMed ID: 30444904)
1. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES
PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904
[TBL] [Abstract][Full Text] [Related]
2. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
Lin ZP; Ratner ES; Whicker ME; Lee Y; Sartorelli AC
Mol Cancer Res; 2014 Mar; 12(3):381-393. PubMed ID: 24413181
[TBL] [Abstract][Full Text] [Related]
3. Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
Ratner ES; Zhu YL; Penketh PG; Berenblum J; Whicker ME; Huang PH; Lee Y; Ishiguro K; Zhu R; Sartorelli AC; Lin ZP
Br J Cancer; 2016 Mar; 114(7):777-86. PubMed ID: 26964031
[TBL] [Abstract][Full Text] [Related]
4. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
7. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
9. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
[TBL] [Abstract][Full Text] [Related]
11. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
12. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
13. In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.
Lin ZP; Al Zouabi NN; Xu ML; Bowen NE; Wu TL; Lavi ES; Huang PH; Zhu YL; Kim B; Ratner ES
Sci Rep; 2021 Apr; 11(1):8042. PubMed ID: 33850183
[TBL] [Abstract][Full Text] [Related]
14. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
16. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
17. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
18. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
Karakashev S; Zhu H; Yokoyama Y; Zhao B; Fatkhutdinov N; Kossenkov AV; Wilson AJ; Simpkins F; Speicher D; Khabele D; Bitler BG; Zhang R
Cell Rep; 2017 Dec; 21(12):3398-3405. PubMed ID: 29262321
[TBL] [Abstract][Full Text] [Related]
19. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Bizzaro F; Fuso Nerini I; Taylor MA; Anastasia A; Russo M; Damia G; Guffanti F; Guana F; Ostano P; Minoli L; Hattersley MM; Arnold S; Ramos-Montoya A; Williamson SC; Galbiati A; Urosevic J; Leo E; Cavallaro U; Ghilardi C; Barry ST; Bani MR; Giavazzi R
J Hematol Oncol; 2021 Nov; 14(1):186. PubMed ID: 34742344
[TBL] [Abstract][Full Text] [Related]
20. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
